Review

Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair ☆

Maciej Lech *, Hans-Joachim Anders

Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians Universität München, Germany

ABSTRACT

Certain macrophage phenotypes contribute to tissue fibrosis, but why? Tissues host resident mononuclear phagocytes for their support to maintain homeostasis. Upon injury the changing tissue microenvironment alters their phenotype and primes infiltrating monocytes toward pro-inflammatory macrophages. Several mechanisms contribute to their deactivation and macrophage priming toward anti-inflammatory and pro-regenerative macrophages that produce multiple cytokines that display immunosuppressive as well as pro-regeneratory effects, such as IL-10 and TGF-beta1. Insufficient parenchymal repair creates a tissue micro-environment that becomes dominated by multiple growth factors that promote the pro-fibrotic macrophage phenotype that itself produces large amounts of such growth factors that further support fibrogenesis. However, the contribution of resident mononuclear phagocytes to physiological extracellular matrix turnover implies also their fibrolytic effects in the late stage of tissue scaring. Fibrolytic macrophages break down fibrous tissue, but their phenotypic characteristics remain to be described in more detail. Together, macrophages contribute to tissue fibrosis because the changing tissue environments prime them to assist and orchestrate all phases of tissue injury and repair. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Fibrogenesis has been maintained throughout evolution because of its live-saving benefits during the wound healing processes that occur after injury. On the other hand fibrogenesis contributes to many chronic progressive disease states.

In general, any kind of injury involves a sequence of responses to control the injurious trigger that restore homeostasis [1]. Tissue loss, either by trauma or by the collateral damage during the inflammatory phase, requires tissue repair, which involves scaring. Cells of the monocyte/macrophage lineage are central players of the immune response following tissue damage. Macrophages have many functions, including the promotion and resolution of inflammation, the removal of apoptotic cells, and the support of cell proliferation following injury. Macrophages exist in several different phenotypic states within the injured tissue and promote inflammation and at the same time are beneficial for the repair of healing tissue.

In this review, we will summarize how mononuclear phagocytes, especially macrophages, are involved in the various stages of tissue injury and repair. The different and specific roles of macrophages during parenchymal repair, mesenchymal repair, and fibrolysis become more obvious from the perspective of the tissues' needs to regain homeostasis upon injury.

2. Phases of tissue injury and repair

2.1. The injury phase

Pathogen entry, toxic or oxidative stress often causes necrotic cell death, which implies the release of damage- and pathogen-associated molecular patterns (DAMPs or PAMPs) released by necrotic cells and/ or microorganisms, respectively. These have an identical capacity to activate toll-like receptors (TLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs) or inflammasomes for the secretion of cytokines and chemokines, which set up tissue inflammation and leukocyte recruitment [2–6]. The associated immunopathology often largely contributes to acute impairment of tissue dysfunction or mortality, e.g. in sepsis, pneumonia, meningitis, or acute kidney injury. The antimicrobial activity of recruited immune cells involves reactive oxygen species production, enzyme and pro-inflammatory cytokine release. Furthermore, a persistent accumulation of immune cells may prolong tissue inflammation and aggravate immunopathology.

2.2. Resolution of inflammation upon control of the injurious trigger

Mechanisms that control inflammatory processes and restore homeostasis are crucial for efficient recovery and preserving tissue morphology and function [7]. Inflammation suppresses tissue repair, which implies that the resolution of inflammation is necessary to tip the balance to parenchymal repair and healing. One of the events participating in these changes is the decreasing amount of DAMPs and PAMPs and the high number of apoptotic neutrophils that need to be removed by macrophages. This process not only turns pro-inflammatory into anti-inflammatory macrophages that secrete large amounts of IL-10 and TGF-β [8,9], but the sequential activation of transcription factors either also promotes inflammation such as NF-κB [10] and IRF-1 [11] and subsequently its resolution like IRF-4 [12,13].

2.3. The epithelial and vascular repair phase

Restoring tissue integrity after any kind of injury may be achieved by proliferation of 1. surviving cells, 2. local progenitor cells, and 3. bone marrow-derived precursors [14,15]. The capacity for tissue regeneration varies between different organs. While blood cells easily and completely regenerate from hematopoietic stem cells inside the bone marrow the capacity of vascular regeneration, again from endothelial progenitors inside the bone marrow, is already somewhat limited, especially in chronic disease states, like uremia [16–18]. Remote cellular compartments in solid organs may not even be accessible to bone marrow-derived stem cells even though these still promote repair by paracrine secretion of growth factors [19]. Therefore, especially epithelial structures, like the epidermis, the intestinal epithelium and renal podocytes or tubular epithelial cells rely on local committed progenitor cells for repair [15,20].

2.4. Mesenchymal repair

Fibrotic tissue seals and mechanically stabilizes the "wound" only when damage is not limited to the epithelium and/or repair is not fast enough [21]. This may involve partial loss of organ function also because fibrosis involves sclerosis that e.g. functionally restricts the flexibility of skin/joints/small bowel; affects electric circuits and hemodynamics in the heart; reduces arteriolar compliance followed by arterial hypertension or causes persistent proteinuria from the renal glomeruli. Cellular and molecular events in mesenchymal healing (fibrosis) include 1. infiltration of immune cells and fibrocytes, 2. accumulation of extracellular matrix (ECM), 3. activation of fibroblasts and myofibroblasts, and 4. angiogenesis [22]. Fibrosis is often associated with persistent inflammation and loss of organ function, i.e. chronic disease [23]. Their causal relationship is often anticipated but remains unclear [24].

2.5. Minimizing scars

Extracellular matrix (ECM) turnover during homeostasis already implies that interstitial cells release proteases and that phagocytes remove ECM breakdown products [25]. Scars shrink by reducing excess ECM via enzymatic activity, e.g. by matrix metalloproteases (MMP). Factors that limit fibrogenesis and promote fibrolysis are prostaglandin E2 [26] or caveolin-1 and BMP7 [27,28]. Furthermore, recombinant TGF-β3 application in humans' skin injury supports ECM breakdown and scarless healing [29]. TGF-β3 application prevents excessive proliferation of myofibroblasts and changes their migration toward a pattern normally seen only in the fetal stage where scarless healing occurs [29].

3. Origin and diversity of monocytic phagocytes in healthy tissues

Macrophage development is controlled by CSF-1R, also known as macrophage colony-stimulating factor-1 receptor, which is expressed on all monocyte progenitors [30]. Ligation of this receptor activates the myeloid developmental regulator PU.1. Mice deficient in CSF-1R or its ligand do not develop any monocyte, macrophages or dendritic cells [31]. Other essential factors responsible for the development of myeloid cells include IRF8, KLF4, c-Maf and many more molecules, which function have not been precisely described yet [30]. The phenotype of circulating monocytes significantly differs in terms of their response to infection and inflammation [32]. Monocytes circulate in blood and migrate into tissues where they mature and develop into macrophages. Human monocytes consist of three subsets which appear to be responsible for different processes. The new classification of monocytes is based on the expression of CD14/CD16 and Ly6C/CD43 in human and mice respectively [32]. CD14++CD16− (in mice Ly6C++CD43+) monocytes are commonly referred to as the 'classical monocytes' which produce high levels of TNF-α and MHC II [33] and are the major population of human monocytes. They also express CCR2 and, therefore, respond to CCL2 for transendothelial migration and secretion of additional pro-inflammatory cytokines [34,35]. Most of these circulating monocytes become pro-inflammatory tissue macrophages once they exit the vasculature. By contrast 'nonclassical' CD14+CD16++ monocytes (in mice Ly6C+CD43++) and 'intermediate' monocytes (CD14++CD16+ subsets in humans and Ly6C++CD43− in mice) are in the minor population. The 'intermediate' subset expresses surface markers at levels between 'classical' and 'nonclassical' subsets [36–38]. 'Nonclassical' monocytes were shown to response poorly to LPS but still are able to produce TNF-α. By contrast CD14++CD16+ 'intermediate' monocytes show high expression of TLR4, increased phagocytic activity and decreased antigen presentation. By contrast LPS-stimulated CD14++CD16+ monocytes produced more IL-10 than 'nonclassical' monocytes and showed anti-inflammatory functions [39]. This heterogeneity of mononuclear phagocytes in healthy or injured tissues relates to different microenvironments in different tissue compartments that also undergo changes during the different phases of dynamic disease processes, which then is associated with shifts toward different monocytic phagocyte populations. This phenotype plasticity is the reason why most of the in vivo studies failed to reveal pure macrophage clusters of a single phenotype [40–42]. A detailed discussion of classifying macrophages by their surface marker expression profiles has been provided elsewhere [41–44]. In vivo, macrophages are present in all tissues and participate in maintaining homeostasis. For example, the lung and liver are exposed to pathogens from the air or pathogen components from the intestines, respectively, which explain the predominance of macrophages that can clear pathogen components by phagocytosis. Also the bone marrow requires macrophages for the clearance of the nuclei expelled from erythroblasts [45]. The intestinal mucosa rather hosts dendritic cells that pick up signals from the microbiota to secrete mitogenic mediators that support the maintenance of the intact epithelial lining [46]. Sterile organs rather harbor dendritic cells that process autoantigens and send tolerogenic signals to lymphocytes in regional lymphnodes as a mechanism of peripheral tolerance [47,48].

Together, already during homeostasis different organs provide unique microenvironments, which generate different shapes and functional properties of their resident mononuclear phagocytes, e.g. resident dendritic cells or rather resident tissue macrophages. Tissue injuries suddenly change the organ-specific environment, which, depending of the type of injury, leads to adaptive changes of the resident mononuclear phagocytes as well as of the infiltrating monocytes.

4. Monocytic phagocytes in the tissue injury/inflammation phase

PAMPs and DAMPs are responsible for generating pro-inflammatory macrophage subsets during infections and sterile tissue injury, respectively, because they activate pattern-recognition receptors on the macrophage surface [4–6]. These macrophages secrete pro-inflammatory

cytokines and chemokines and attract other immune cells such as neutrophils or natural killer cells [49,50]. Furthermore, such activated macrophages have the ability to kill intracellular bacteria and have a phenotype proposed by in vitro studies as M1 macrophages (Fig. 1, Table 1). M1a macrophages were defined by IFN-γ and LPS stimulation, whereas M1b macrophages by stimulation with PAMPs. Generally, inflammatory M1a macrophages secrete IL-1, IL-12, IL-23, tumor necrosis factor (TNF)-α and reactive oxygen species. They express high levels of inducible nitric oxide synthase, major histocompatibility complex class II (MHCII^{high}) and IL-1R [42]. They have enhanced phago- and endocytic abilities and increased expression of co-receptors required for antigen presentation but cannot efficiently ingest apoptotic cells. This bactericidal macrophage phenotype appears in the early phases of tissue injury shortly to enforce local host defense against pathogens, a process that is potentially life-saving during infections but also causes collateral tissue damage [42,51,52]. However, sterile injuries induce inflammation similar to injury caused by pathogens [42,51,52]. M1b macrophages which predominantly develop in these conditions have been described to being activated after endogenous danger signals, such as HMGB1, iron, histones or ATP, ligate pattern recognition receptors [42,51–53]. Such sterile injuries can occur in many organs [54–56]. Although inflammation plays an important function in limiting the numbers of pathogens, it limits also the epithelial healing and induces tissue damage and dysfunction. This finding was supported by showing an improved re-epithelialization of sterile wounds in *PU.1*-deficient mice that lack neutrophils and macrophages, or in *Myd88*-deficient mice that have impaired innate immune responses [57–59]. Additionally, reactive oxygen species or TNF-α was shown to promote cell cycle arrest or apoptosis in epithelial and endothelial cells. A persistent pro-inflammatory macrophage phenotype is sufficient to turn acute into chronic tissue inflammation and progressive loss of tissue [60]. Classically-activated pro-inflammatory macrophages amplify inflammation and loss of parenchymal cells also in a variety of kidney diseases such as in anti-glomerular basement membrane glomerulonephritis

[61], lupus nephritis [62–67], antigen-induced immune complex glomerulonephritis [68], renal allograft injury [69], ischemia reperfusion injury [70–73], and adriamycin nephropathy [74]. Blocking the recruitment and activation of M1 macrophages reduces immunopathology in a number of inflammatory kidney disease models [75–77]. These observations do not only apply to the kidney, but also to autoimmune diseases of the central nervous system [78,79], CCl4-induced liver injury and several other infectious and noninfectious types of inflammation in solid organs [7,80]. However, some studies also document that wound closure is significantly delayed upon early macrophage depletion [81].

Also in sterile wounds the depletion of pro-inflammatory macrophages leads to reduced scar areas [81], but in sterile environments the inflammatory phase is short-lasting. Therefore, sterile wounds heal faster [14,82]. This is also because immunomodulatory elements rapidly downregulate the inflammatory response and promote tissue repair [83]. It is of note that certain macrophage phenotypes contribute to this anti-inflammatory and pro-regeneratory phase of tissue injury and repair.

5. Monocytic phagocytes during the resolution of inflammation

The sequential influx of neutrophils and macrophages upon injury is a hallmark of acute tissue damage. Macrophages are needed to remove those neutrophils that undergo NETosis or apoptosis (Fig. 1) [84]. The phagocytosis of apoptotic cells is a central element that changes the phenotype of pro-inflammatory macrophages into anti-inflammatory macrophages and subsequently promotes the resolution of inflammation [85,86]. This 'waste elimination process' avoids persistent exposure of immunostimulatory elements to immune cells. Furthermore, such alternatively-activated macrophages release mediators such as IL-4, IL-13, IL-10 or transforming growth factor-β1 (TGF-β1) that rather shift tissue inflammation toward tissue repair [8,9,87]. A key regulator of these processes may be circulating serum amyloid P also known as pentraxin-2 (PTX-2), which opsonizes dead


Fig. 1. Macrophages and renal fibrosis. Tissue damage activates parenchymal cells, which results in subsequent activation of innate immunity. This includes the recruitment of monocytes that differentiate into various macrophage phenotypes depending on the local tissue environment. Pathogens and necrotic cells release factors that activate toll-like and other innate immune receptors that drive macrophage polarization toward the 'M1' proinflammatory macrophage. By contrast, the phagocytic uptake of apoptotic cells and other anti-inflammatory signals favors macrophage polarization toward anti-inflammatory or profibrotic 'M2' phenotypes. Fibrolytic macrophages release proteases which digest ECM.

Table 1
Types of macrophage activation and their related phenotypes.

IFN-γ + PAMPs	DAMPs or LPS	IL-4 or IL-13	IC + LPS	IL-10 or TGF-β
Stimuli (evidence from in vitro studies)				
M1a	M1b	M2a	M2b	M2c
Classic type I inflammation	Innate inflammation	Alternative type II inflammation	Immunoregulatory	Immunosuppression
Predominant phenotypic function in inflammation and repair processes				
Ingestion of pathogens, antigen presentation, complement synthesis, stimulation of Th1 cells	Ingestion of apoptotic cells	Recruitment of Th2 cells, eosinophils and basophils, killing of intracellular pathogens such as helminths	Promote Th2 responses, IgG class switching by B-cells, matrix synthesis	Resolution of inflammation, matrix synthesis and remodeling
Inflammatory expression profile and determinants of polarization				
+ regulation: STAT1/IRF5 CD40, CD80, CD86, MHC I and II, IL-1β, TNF-α, IL-6, -12, -15, -18, -23, iNOS, NO, ROS, CCL-2, -3, -5, -8, -15, -19, -20, CXCL-9, -10, -11, -13, MMPs − regulation: scavenger receptors, TIMPs IL-4, -13, -10, TGF-β mTOR	+ regulation: STAT1/IRF5 CD40, CD80, CD86, MHC II, IL-1β, TNF-α, IL-6, ROS, CCL2, 3, 5, CXCL9, 10, 11, scavenger receptor − regulation: IL-12, IL-4, IL-13, IL-10, TGF-β mTOR	+ regulation: STAT6/IRF4 PPARδ, PPRγ, KLF4, IGF-1, Arg1, CD40, CD80, CD86, MHC II, CCL2, 8, 13, 17, 26, CXCL9, 10, 11, 13, FIZZ1, YM1, scavenger receptor, mannose receptor, DC-SIGN, FcγR, IL-10, IL-1RA, IL-1RII, MMP12, TGF-β, mTOR, fibronectin − regulation: IL-1β, IL-12, NO	+ regulation: IL-10, CD40, CD80, CD86, MHC II, CXCL-3, CCL-1, -20, mTOR − regulation: IL-12 secretion of modest amount of: IL-1β, IL-6, TNF-α	+ regulation: STAT3, scavenger receptors A and B, IL-10, IL-1RA, TGF-β, mannose receptor, VEGF-C, PDGF, Arg-1, PGE2, FcγRs, CCR-1, -2, -5, CCL-16, -18, CXCL-4, -13, -23, SLAM, mTOR − regulation: IL-1β, TNF-α, IL-6, -12

Depending upon the nature of the activating stimulus activated macrophages alter their expression of cytokines, costimulatory molecules and cytotoxic apparatus to promote the response to pathogens. M1-polarization, or classical activation, is induced by IFN-γ combined with microbial stimuli (PAMPs and DAMPs). M2-polarized macrophages have been classified into three groups: M2a, M2b and M2c. M2a macrophages (alternatively activated macrophages), are induced by IL-4 or IL-13 treatment. M2b macrophages arise upon stimulation with immune complexes. M2c macrophages (deactivated or regulatory macrophages), are anti-inflammatory macrophages generated by exposure to such stimuli as IL-10 or TGF-β. M1-polarized macrophages cross talk with Th1 and NK cells. M2 polarization of macrophages is driven by Th2 cells, basophils and eosinophils through their secretion of IL-4 or IL-13. M2b-like macrophages are polarized by interaction with B cells through antibody-/immune-complexes-mediated activation. M2c-like macrophages are polarized by interaction with Treg cells. Molecular pathways of macrophage polarization include activation of the transcription factors NF-κB (p65 and p50), AP-1, IRFs and STATs, which leads to the transcription of appropriate genes (cytokines, growth factors and surface molecules).

cells in injured tissues [88,89]. In vitro studies have classified alternatively-activated M2 macrophages into three subtypes: (1) M2a activated by IL-4 or IL-13, (2) M2b activated by immune complexes and LPS, and (3) M2c activated by IL-10 and TGF-β1 (Table 1). Generally, M2 macrophages express high levels of the mannose receptors, of scavenger receptor A as well as FIZZ1 and YM1. Furthermore, they produce CCL13, CCL8 or CCL26, which recruits eosinophils, basophils, and Th2 T cells, a program which derives from host defence against extracellular pathogens [90]. Experimental studies showed that direct IL-4/IL-10 treatment or genetically modified or transfused IL-10-stimulated macrophages help to resolve renal inflammation [91–94]. IL-10, which strongly activates M2c macrophages, was proposed to be a predominant cytokine that orchestrates the resolution of inflammation. Further evidence for this concept is provided by studies with tumor associated macrophages (TAMs), which create a non-inflammatory tumor environment. TAMs secrete large amounts of IL-10, VEGF and PDGF, which are necessary for angiogenesis and building the tumor stroma, conceptually like a chronic wound [95,96]. M2 macrophage injection into mice was protective in terms of inflammatory cytokine expression and accumulation of pro-inflammatory macrophages [93]. Also steroids suppress kidney inflammation by inducing anti-inflammatory macrophages [97]. However, depletion of anti-inflammatory M2 macrophage reduced muscle regeneration [21] as well as axonal regeneration after sterile spinal cord injury [98]. Similar positive effect of M2 macrophages on healing processes was observed during toxic CCl4-induced liver disease [99] and hepatic ischemia/reperfusion injury [100]. Moreover, macrophage depletion from sterile wounds not only delays wound healing but also leads to apoptosis of endothelial cells [81]. Thus, the switch to an anti-inflammatory macrophage phenotype supports the resolution of inflammation, a mandatory step for efficient tissue repair.

6. Monocytic phagocytes during tissue repair and fibrosis

Scarless wound healing occurs in lower animals even in non-sterile conditions. In mammals and even human fetuses it is limited to the sterile fetal environment or during childhood where tissue growth involves a higher density of tissue progenitors than in adults [101]. The process of scarring was evolutionarily conserved and is necessary to address the loss of tissues that cannot rapidly or only incompletely regenerate. Insufficient repair is associated with the persistence of alternatively-activated macrophages that continue to produce growth factors, which also stimulate fibroblast activation and ECM secretion [51]. For example, M2 macrophages secrete large amounts of transforming growth factor-β (TGF-β), a cytokine with anti-inflammatory as well as pro-fibrotic functions [95]. Other pro-fibrotic factors are CTGF, CCL17, CCL22, and Igf1. TGF-β is also up-regulated in epithelial cells that can no longer proliferate for repair and, therefore, produce TGF-β and CTGF to activate mesenchymal healing as a second line healing program [102]. In vitro, IL-4 and IL-13 induce STAT6 signaling to promote a macrophage phenotype that predominantly releases ECM molecules [42] and blocks inflammation [103]. Furthermore, arginase expressed by M2 macrophages can directly promote fibrogenesis by activating the synthesis of glutamate and proline which are necessary for collagen synthesis [104]. Macrophage-induced anti-inflammatory/pro-fibrotic responses occur inside solid organs following transient sterile inflammation, such as ischemia/reperfusion [72]. In the heart, macrophages orchestrate myocardial remodeling upon myocardial infarction [105]. For example after renal ischemia/reperfusion injury the phenotypic switch from pro-inflammatory toward anti-inflammatory macrophages is driven by tubular epithelial cell-derived factors as well as by the uptake of apoptotic neutrophils [72,106]. Progression of glomerulosclerosis and interstitial fibrosis in murine Alport syndrome of *collagen 4A3*-deficient mice is also associated with significant M2 macrophage infiltrates [107]. Therefore, blocking the recruitment and activation of pro-inflammatory macrophages, e.g. with CCL2 antagonist, remained ineffective in Alport syndrome as these cells do not contribute to the progression of renal scaring [108]. The same applies to hepatic fibrosis [109,110]. In contrast, blocking CCR1, a chemokine receptor also expressed by anti-inflammatory and pro-regeneratory M2 macrophages, reduced macrophages, subsequent fibrosis, and prolonged survival of *collagen 4A3*-deficient mice [111]. The pro-fibrotic role of CCR1+ interstitial macrophages was also confirmed in diabetic

nephropathy of db/db mice, adriamycin-induced nephropathy, and renal fibrosis after unilateral ureteral obstruction [112–116].

Another crucial population of immune macrophage-like immune cells that contributes to tissue repair is circulating fibrocytes [117]. Fibrocytes express the hematopoietic marker CD45 and the progenitor marker CD34 but they also secrete large amounts of collagen-1 [118]. Fibrocytes display a mixed phenotype between monocytic precursors and fibroblasts [119]. During inflammatory responses fibrocytes enter the tissue using surface CXCR4 receptor, which binds CXCL12 and participates in tissue repair [120]. Consequently, elevated CXCL12 levels were associated with accumulation of fibrocytes in patients with fibrotic lung disease [121], and the presence of these cells correlated with early mortality of patients with idiopathic pulmonary fibrosis [122]. In scleroderma patients, dermal fibrocyte numbers correlate with age and the stage of dermal fibrosis [123]. They seem to possess a unique ability to differentiate into fibroblasts and into myofibroblasts upon stimulation with TGF-β [124–126]. More recently, it has been shown that also CXCR3 + hematopoietic cells might be the subset responsible for scar formation/fibrosis [127].

Together, macrophages contribute to tissue fibrosis only because they support a mesenchymal healing response that is activated once epithelial/parenchymal repair remains insufficient. This is driven by a microenvironment of apoptotic cells and growth factors that drive macrophages to themselves produce pro-fibrotic mediators. In chronic disorders, especially in diffuse injuries, the process of fibrosis then accompanies the progressive loss of function, which largely depends on the loss of parenchyma. However, sclerosis, the functional consequence of fibrosis, can contribute to disease progression, e.g. the stiffening of the cardiac ventricles or of the vascular wall.

7. Monocytic phagocytes during the resolution of fibrosis

Distinct macrophage populations also limit or even reverse tissue fibrosis by digesting ECM deposits. Two proteolytic cascades, the matrix metalloproteinases (MMPs) and their endogenous inhibitors (the tissue inhibitors of metalloproteinases-TIMPs, the plasminogen activators uPA and tPA, and the plasminogen activator inhibitors-PAIs), regulate matrix turnover [128,129]. However, the role of MMPs in fibrosis is complex and seems to be compartment, – time – and cell type-specific. The in vivo effects remain difficult to predict because MMPs also cleave and activate a variety of cytokines. Several studies suggest an increase in MMP expression, rather than a loss of MMPs, during fibrosis [130,131]. For example, MMP-2, MMP-7 and MMP-9 were elevated in experimental models of lung fibrosis and their overexpression was shown to promote fibrogenesis [132–134]. They are most probably involved in basement membrane digestion, which leads to a loss of structural integrity and contributes to parenchymal damage and dysfunction. Furthermore, Mmp7-deficient mice are protected from bleomycin-induced fibrosis [132]. However, when macrophages are depleted in the late phase of toxic liver fibrosis the clearance of liver scars is delayed, because scar-associated macrophages no longer release MMP13, which breaks down ECM [135]. Various MMPs have been implicated in the severity of inflammation and fibrosis in asbestos-induced lung injury and MMP blockade attenuated inflammation and fibrosis [136]. For example, pirfenidone, an anti-fibrotic agent that decreases collagen deposition in a variety of animal models and humans is believed to modulate MMP activity [137]. In some experimental models, pirfenidone reduced the expression of TIMP-1, MMP-2 and MMP-9 but not of MMP-13, which was associated to less TGF-β1 expression [137–139]. Macrophages also release MMP2 and MMP9 that degrade collagen in the kidney [140,141]. Interestingly, late onset of MMP inhibition in mice with progressive renal scaring aggravated renal fibrosis, while it was protective during the early stage of the disease [142]. It seems that certain MMPs do not only degrade collagen but also rather digest ECM including basement membranes, which compromises the integrity of epithelial compartments [143]. ECM break

down also produces small ECM peptides and glycosaminoglycans, which themselves can act as immunostimulatory DAMPs and potentiate tissue inflammation [144]. Fibrolytic macrophages have such an excessive fibrolytic activity but their phenotype has not yet been clearly defined, e.g. by their specific surface marker expression profile. Recent studies showed that treatment of cultured macrophages with M-CSF, but not GM-CSF, shifts macrophages from antigen-presenting cells to subpopulation of IL-10-producing suppressor cells [145]. IL-10 has immunosuppressive function, which acts on macrophages and prevents them from production of proinflammatory cytokines, and to downregulate expression of co-stimulatory molecules in a STAT3-dependent manner [146–148]. Moreover, IL-10 produced by suppressor macrophages prevents the development of Th1-type and Th2 T-cell responses, and promotes the differentiation of T cells to regulatory T-cell population [149]. Also proinflammatory factors such as IFN-γ or IL-12 may induce regulatory macrophage population. Various studies demonstrated that continuous exposure of macrophages to TLR2, TLR4 or TLR9 ligands leads to development of immunosuppressive state [150–152].

Latest studies identified also non-proteolytic and antifibrotic factors such as BMP7. BMP7 is one of over 20 known members of BMP family that are structurally and functionally related and are part of TGF superfamily of cytokines [153]. BMP7 is indispensable for normal kidney development [154]. However, unlike TGF-β, BMP7 was found to be downregulated in experimental and human fibrosis [28,155]. Furthermore, the kidney mesenchymal cells of BMP7 null embryos were not able to differentiate [156]. Other studies have demonstrated that BMP7 protects the kidney from injury by enhancing the survival ability of tubular cells and reduction of inflammation [157,158]. Therefore, BMP7 might be a crucial survival and differentiation factor for kidney mesenchymal cells.

Taken together, macrophages already contribute to the breakdown and turnover of ECM during homeostasis but this property becomes more prominent in the microenvironment of scar tissue. Removing fibrous tissue is the final phase of the wound healing process. Activating the fibrolytic properties of these macrophages may be another option to reverse tissue fibrosis. Such fibrolytic macrophage populations have been described in some organs but deserve further phenotypic characterization.

8. Summary

Tissue mononuclear phagocytes can display a phenotype of resident dendritic cells or of resident macrophages, but they are important for maintaining homeostasis. During tissue injury changing tissue environments shape the phenotype of these mononuclear phagocytes to provide them with additional functional properties that meet the tissues' need to address the danger. It is instrumental to apply the model of (dermal) wound healing upon traumatic injury to better understand their role in each of the phases of danger control and tissue repair also in other organs. Accordingly, pro-inflammatory (M1) macrophages support host defense by enhancing the inflammatory environment even in sterile tissue injuries. The inflammatory response following tissue injury has important roles in both normal and pathological healing. Immediately after injury, the innate immune system is activated and is responsible for recruitment of inflammatory cells from the circulation. Local, resident immune cells, including macrophages produce chemoattractans that enhance inflammatory responses by recruiting more leukocytes. Understanding of macrophage population switch and mechanisms which regulate macrophage function seems to be an attractive therapeutic target, both to reduce fibrosis and scarring, and to improve healing of chronic wounds. It seems that during normal inflammation, which includes mast cell degranulation and neutrophil infiltration, macrophages have an important balancing role. Thus, the role of macrophages must always be considered in the context of the specific environment.

Anti-inflammatory macrophages support the resolution of inflammation. This process involves the expression of growth factors that promote parenchymal repair, which includes mesenchymal repair. For example, the anti-inflammatory cytokine TGF-β1 is a potent pro-fibrotic cytokine that activates mesenchymal repair mechanisms.

Finally, macrophages contribute to the removal of fibrous tissue. Mediating the resolution phase of healing includes capillary regression and collagen remodeling. Macrophages can produce factors that terminate the repair response. However, little is known about how a particular population of macrophages terminates the healing response but the agent modulating the phenotype of these particular macrophages or ex-vivo production of such cells possesses great therapeutic potential. Furthermore, using single macrophage factors as therapeutics raise difficulties with optimum delivery systems, timing and concentration, not to mention the proteolytic condition which limits the half-life of therapeutic agents. One alternative would be in situ activation, recruitment or addition of exogenous macrophages which are source of beneficial growth factors and cytokines that stimulate regeneration of damaged tissue, angiogenesis and actively leads to resolution of established fibrosis. However, increasing the number of macrophages in the fibrotic tissue might imbalance the environment and macrophages might switch again the phenotype and potentiate inappropriate conditions such as inflammation instead of resolution of fibrotic tissue or regeneration. The strategy of driving macrophages within tissue toward a suppressor phenotype might be a promising therapeutic approach opening a novel area of cell-based medicinal products.

Acknowledgement

References

[1] H.J. Anders, Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing, Organogenesis 8 (2012) 29–40.

[2] M. Lamkanfi, V.M. Dixit, Inflammasomes and their roles in health and disease, Annu. Rev. Cell Dev. Biol. 28 (2012) 137–161.

[3] D. Sancho, C. Reis e Sousa, Signaling by myeloid C-type lectin receptors in immunity and homeostasis, Annu. Rev. Immunol. 30 (2012) 491–529.

[4] M. Lech, A. Avila-Ferrufino, V. Skuginna, H.E. Susanti, H.J. Anders, Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice, Int. Immunol. 22 (2010) 717–728.

[5] M. Lech, H.E. Susanti, C. Rommele, R. Grobmayr, R. Gunthner, H.J. Anders, Quantitative expression of C-type lectin receptors in humans and mice, Int. J. Mol. Sci. 13 (2012) 10113–10131.

[6] O. Takeuchi, S. Akira, Pattern recognition receptors and inflammation, Cell 140 (2010) 805–820.

[7] T.T. MacDonald, I. Monteleone, M.C. Fantini, G. Monteleone, Regulation of homeostasis and inflammation in the intestine, Gastroenterology 140 (2011) 1768–1775.

[8] R.E. Voll, M. Herrmann, E.A. Roth, C. Stach, J.R. Kalden, I. Girkontaite, Immunosuppressive effects of apoptotic cells, Nature 390 (1997) 350–351.

[9] V.A. Fadok, D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, P.M. Henson, Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF, J. Clin. Invest. 101 (1998) 890–898.

[10] J.A. DiDonato, F. Mercurio, M. Karin, NF-kappaB and the link between inflammation and cancer, Immunol. Rev. 246 (2012) 379–400.

[11] Y. Wang, R. John, J. Chen, J.A. Richardson, J.M. Shelton, M. Bennett, X.J. Zhou, G.T. Nagami, Y. Zhang, Q.Q. Wu, C.Y. Lu, IRF-1 promotes inflammation early after ischemic acute kidney injury, J. Am. Soc. Nephrol. 20 (2009) 1544–1555.

[12] S. Lassen, M. Lech, C. Rommele, H.W. Mittruecker, T.W. Mak, H.J. Anders, Ischemia reperfusion induces IFN regulatory factor 4 in renal dendritic cells, which suppresses postischemic inflammation and prevents acute renal failure, J. Immunol. 185 (2010) 1976–1983.

[13] T. Tamura, H. Yanai, D. Savitsky, T. Taniguchi, The IRF family transcription factors in immunity and oncogenesis, Annu. Rev. Immunol. 26 (2008) 535–584.

[14] G.C. Gurtner, S. Werner, Y. Barrandon, M.T. Longaker, Wound repair and regeneration, Nature 453 (2008) 314–321.

[15] E.N. Arwert, E. Hoste, F.M. Watt, Epithelial stem cells, wound healing and cancer, Nat. Rev. Cancer 12 (2012) 170–180.

[16] R. Kramann, S.K. Couson, S. Neuss, J. Floege, R. Knuchel, R.K. Schneider, Uraemia disrupts the vascular niche in a 3D co-culture system of human mesenchymal stem cells and endothelial cells, Nephrol. Dial. Transplant. 27 (2012) 2693–2702.

[17] K. de Groot, F.H. Bahlmann, J. Sowa, J. Koenig, J. Menne, H. Haller, D. Fliser, Uremia causes endothelial progenitor cell deficiency, Kidney Int. 66 (2004) 641–646.

[18] P. Brunet, B. Gondouin, A. Duval-Sabatier, L. Dou, C. Cerini, F. Dignat-George, N. Jourde-Chiche, A. Argiles, S. Burtey, Does uremia cause vascular dysfunction? Kidney Blood Press. Res. 34 (2011) 284–290.

[19] A.I. Caplan, D. Correa, The MSC: an injury drugstore, Cell Stem Cell 9 (2011) 11–15.

[20] E. Lazzeri, B. Mazzinghi, P. Romagnani, Regeneration and the kidney, Curr. Opin. Nephrol. Hypertens. 19 (2010) 248–253.

[21] L. Arnold, A. Henry, F. Poron, Y. Baba-Amer, N. van Rooijen, A. Plonquet, R.K. Gherardi, B. Chazaud, Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis, J. Exp. Med. 204 (2007) 1057–1069.

[22] T.A. Wynn, Cellular and molecular mechanisms of fibrosis, J. Pathol. 214 (2008) 199–210.

[23] M.A. Vernon, K.J. Mylonas, J. Hughes, Macrophages and renal fibrosis, Semin. Nephrol. 30 (2010) 302–317.

[24] H.J. Anders, M. Ryu, Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis, Kidney Int. 80 (2011) 915–925.

[25] J.D. Mott, Z. Werb, Regulation of matrix biology by matrix metalloproteinases, Curr. Opin. Cell Biol. 16 (2004) 558–564.

[26] K.A. Bauman, S.H. Wettlaufer, K. Okunishi, K.M. Vannella, J.S. Stoolman, S.K. Huang, A.J. Courey, E.S. White, C.M. Hogaboam, R.H. Simon, G.B. Toews, T.H. Sisson, B.B. Moore, M. Peters-Golden, The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice, J. Clin. Invest. 120 (2010) 1950–1960.

[27] X.M. Wang, Y. Zhang, H.P. Kim, Z. Zhou, C.A. Feghali-Bostwick, F. Liu, E. Ifedigbo, X. Xu, T.D. Oury, N. Kaminski, A.M. Choi, Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis, J. Exp. Med. 203 (2006) 2895–2906.

[28] M. Zeisberg, J. Hanai, H. Sugimoto, T. Mammoto, D. Charytan, F. Strutz, R. Kalluri, BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury, Nat. Med. 9 (2003) 964–968.

[29] N.L. Occleston, S. O'Kane, H.G. Laverty, M. Cooper, D. Fairlamb, T. Mason, J.A. Bush, M.W. Ferguson, Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring, Wound Repair Regen. 19 (Suppl. 1) (2011) s38–s48.

[30] C. Auffray, M.H. Sieweke, F. Geissmann, Blood monocytes: development, heterogeneity, and relationship with dendritic cells, Annu. Rev. Immunol. 27 (2009) 669–692.

[31] V. Chitu, E.R. Stanley, Colony-stimulating factor-1 in immunity and inflammation, Curr. Opin. Immunol. 18 (2006) 39–48.

[32] L. Ziegler-Heitbrock, P. Ancuta, S. Crowe, M. Dalod, V. Grau, D.N. Hart, P.J. Leenen, Y.J. Liu, G. MacPherson, G.J. Randolph, J. Scherberich, J. Schmitz, K. Shortman, S. Sozzani, H. Strobl, M. Zembala, J.M. Austyn, M.B. Lutz, Nomenclature of monocytes and dendritic cells in blood, Blood 116 (2010) e74–e80.

[33] K.U. Belge, F. Dayyani, A. Horelt, M. Siedlar, M. Frankenberger, B. Frankenberger, T. Espevik, L. Ziegler-Heitbrock, The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF, J. Immunol. 168 (2002) 3536–3542.

[34] F. Geissmann, S. Jung, D.R. Littman, Blood monocytes consist of two principal subsets with distinct migratory properties, Immunity 19 (2003) 71–82.

[35] C. Auffray, D. Fogg, M. Garfa, G. Elain, O. Join-Lambert, S. Kayal, S. Sarnacki, A. Cumano, G. Lauvau, F. Geissmann, Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior, Science 317 (2007) 666–670.

[36] P. Ancuta, R. Rao, A. Moses, A. Mehle, S.K. Shaw, F.W. Luscinskas, D. Gabuzda, Fractalkine preferentially mediates arrest and migration of CD16+ monocytes, J. Exp. Med. 197 (2003) 1701–1707.

[37] P. Ancuta, K.Y. Liu, V. Misra, V.S. Wacleche, A. Gosselin, X. Zhou, D. Gabuzda, Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16− monocyte subsets, BMC Genomics 10 (2009) 403.

[38] J. Cros, N. Cagnard, K. Woollard, N. Patey, S.Y. Zhang, B. Senechal, A. Puel, S.K. Biswas, D. Moshous, C. Picard, J.P. Jais, D. D'Cruz, J.L. Casanova, C. Trouillet, F. Geissmann, Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors, Immunity 33 (2010) 375–386.

[39] J. Skrzeczynska-Moncznik, M. Bzowska, S. Loseke, E. Grage-Griebenow, M. Zembala, J. Pryjma, Peripheral blood CD14high CD16+ monocytes are main producers of IL-10, Scand. J. Immunol. 67 (2008) 152–159.

[40] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol. 8 (2008) 958–969.

[41] S. Gordon, P.R. Taylor, Monocyte and macrophage heterogeneity, Nat. Rev. Immunol. 5 (2005) 953–964.

[42] A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, M. Locati, The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol. 25 (2004) 677–686.

[43] A. Sica, A. Mantovani, Macrophage plasticity and polarization: in vivo veritas, J. Clin. Invest. 122 (2012) 787–795.

[44] S.D. Ricardo, H. van Goor, A.A. Eddy, Macrophage diversity in renal injury and repair, J. Clin. Invest. 118 (2008) 3522–3530.

[45] H. Yoshida, K. Kawane, M. Koike, Y. Mori, Y. Uchiyama, S. Nagata, Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells, Nature 437 (2005) 754–758.

[46] B. Swiatczak, M. Rescigno, How the interplay between antigen presenting cells and microbiota tunes host immune responses in the gut, Semin. Immunol. 24 (2012) 43–49.

[47] I. Zanoni, F. Granucci, The regulatory role of dendritic cells in the induction and maintenance of T-cell tolerance, Autoimmunity 44 (2011) 23–32.

[48] P.J. Nelson, A.J. Rees, M.D. Griffin, J. Hughes, C. Kurts, J. Duffield, The renal mono-nuclear phagocytic system, J. Am. Soc. Nephrol. 23 (2012) 194–203.

[49] T. Kawai, S. Akira, Toll-like receptors and their crosstalk with other innate recep-tors in infection and immunity, Immunity 34 (2011) 637–650.

[50] P.S. Patole, S. Schubert, K. Hildinger, S. Khandoga, A. Khandoga, S. Segerer, A. Henger, M. Kretzler, M. Werner, F. Krombach, D. Schlondorff, H.J. Anders, Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis, Kidney Int. 68 (2005) 2582–2587.

[51] S.J. Galli, N. Borregaard, T.A. Wynn, Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils, Nat. Immunol. 12 (2011) 1035–1044.

[52] K.L. Rock, J.J. Lai, H. Kono, Innate and adaptive immune responses to cell death, Immunol. Rev. 243 (2011) 191–205.

[53] R. Allam, C.R. Scherbaum, M.N. Darisipudi, S.R. Mulay, H. Hagele, J. Lichtnekert, J.H. Hagemann, K.V. Rupanagudi, M. Ryu, C. Schwarzenberger, B. Hohenstein, C. Hugo, B. Uhl, C.A. Reichel, F. Krombach, M. Monestier, H. Liapis, K. Moreth, L. Schaefer, H.J. Anders, Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4, J. Am. Soc. Nephrol. 23 (2012) 1375–1388.

[54] H.J. Anders, Toll-like receptors and danger signaling in kidney injury, J. Am. Soc. Nephrol. 21 (2010) 1270–1274.

[55] M. Benoit, B. Desnues, J.L. Mege, Macrophage polarization in bacterial infections, J. Immunol. 181 (2008) 3733–3739.

[56] H. Kono, K.L. Rock, How dying cells alert the immune system to danger, Nat. Rev. Immunol. 8 (2008) 279–289.

[57] L. Cooper, C. Johnson, F. Burslem, P. Martin, Wound healing and inflammation genes revealed by array analysis of 'macrophageless' PU.1 null mice, Genome Biol. 6 (2005) R5.

[58] P. Martin, D. D'Souza, J. Martin, R. Grose, L. Cooper, R. Maki, S.R. McKercher, Wound healing in the PU.1 null mouse—tissue repair is not dependent on inflammatory cells, Curr. Biol. 13 (2003) 1122–1128.

[59] L. Macedo, G. Pinhal-Enfield, V. Alshits, G. Elson, B.N. Cronstein, S.J. Leibovich, Wound healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors, Am. J. Pathol. 171 (2007) 1774–1788.

[60] A. Sindrilaru, T. Peters, S. Wieschalka, C. Baican, A. Baican, H. Peter, A. Hainzl, S. Schatz, Y. Qi, A. Schlecht, J.M. Weiss, M. Wlaschek, C. Sunderkotter, K. Scharffetter-Kochanek, An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice, J. Clin. Invest. 121 (2011) 985–997.

[61] Y. Ikezumi, R.C. Atkins, D.J. Nikolic-Paterson, Interferon-gamma augments acute macrophage-mediated renal injury via a glucocorticoid-sensitive mechanism, J. Am. Soc. Nephrol. 14 (2003) 888–898.

[62] H.J. Anders, V. Vielhauer, V. Eis, Y. Linde, M. Kretzler, G. Perez de Lema, F. Strutz, S. Bauer, M. Rutz, H. Wagner, H.J. Grone, D. Schlondorff, Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice, FASEB J. 18 (2004) 534–536.

[63] R. Allam, R.D. Pawar, O.P. Kulkarni, V. Hornung, G. Hartmann, S. Segerer, S. Akira, S. Endres, H.J. Anders, Viral 5′-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses, Eur. J. Immunol. 38 (2008) 3487–3498.

[64] P.S. Patole, R.D. Pawar, J. Lichtnekert, M. Lech, O.P. Kulkarni, A. Ramanjaneyulu, S. Segerer, H.J. Anders, Coactivation of toll-like receptor-3 and -7 in immune complex glomerulonephritis, J. Autoimmun. 29 (2007) 52–59.

[65] P.S. Patole, H.J. Grone, S. Segerer, R. Ciubar, E. Belemezova, A. Henger, M. Kretzler, D. Schlondorff, H.J. Anders, Viral double-stranded RNA aggravates lupus nephritis through toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells, J. Am. Soc. Nephrol. 16 (2005) 1326–1338.

[66] R.D. Pawar, P.S. Patole, A. Ellwart, M. Lech, S. Segerer, D. Schlondorff, H.J. Anders, Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis, J. Am. Soc. Nephrol. 17 (2006) 3365–3373.

[67] R.D. Pawar, P.S. Patole, D. Zecher, S. Segerer, M. Kretzler, D. Schlondorff, H.J. Anders, Toll-like receptor-7 modulates immune complex glomerulonephritis, J. Am. Soc. Nephrol. 17 (2006) 141–149.

[68] H.J. Anders, B. Banas, Y. Linde, L. Weller, C.D. Cohen, M. Kretzler, S. Martin, V. Vielhauer, D. Schlondorff, H.J. Grone, Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors, J. Am. Soc. Nephrol. 14 (2003) 317–326.

[69] M.D. Jose, Y. Ikezumi, N. van Rooijen, R.C. Atkins, S.J. Chadban, Macrophages act as effectors of tissue damage in acute renal allograft rejection, Transplantation 76 (2003) 1015–1022.

[70] S. Swaminathan, M.D. Griffin, First responders: understanding monocyte-lineage traffic in the acutely injured kidney, Kidney Int. 74 (2008) 1509–1511.

[71] J.V. Bonventre, A. Zuk, Ischemic acute renal failure: an inflammatory disease? Kidney Int. 66 (2004) 480–485.

[72] S. Lee, S. Huen, H. Nishio, S. Nishio, H.K. Lee, B.S. Choi, C. Ruhrberg, L.G. Cantley, Distinct macrophage phenotypes contribute to kidney injury and repair, J. Am. Soc. Nephrol. 22 (2011) 317–326.

[73] M. Lech, A. Avila-Ferrufino, R. Allam, S. Segerer, A. Khandoga, F. Krombach, C. Garlanda, A. Mantovani, H.J. Anders, Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptor-related protein, J. Immunol. 183 (2009) 4109–4118.

[74] Y. Wang, Q. Cao, G. Zheng, V.W. Lee, D. Zheng, X. Li, T.K. Tan, D.C. Harris, By homing to the kidney, activated macrophages potently exacerbate renal injury, Am. J. Pathol. 172 (2008) 1491–1499.

[75] O. Kulkarni, D. Eulberg, N. Selve, S. Zollner, R. Allam, R.D. Pawar, S. Pfeiffer, S. Segerer, S. Klussmann, H.J. Anders, Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice, J. Pharmacol. Exp. Ther. 328 (2009) 371–377.

[76] O. Kulkarni, R.D. Pawar, W. Purschke, D. Eulberg, N. Selve, K. Buchner, V. Ninichuk, S. Segerer, V. Vielhauer, S. Klussmann, H.J. Anders, Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice, J. Am. Soc. Nephrol. 18 (2007) 2350–2358.

[77] V. Vielhauer, O. Kulkarni, C.A. Reichel, H.J. Anders, Targeting the recruitment of monocytes and macrophages in renal disease, Semin. Nephrol. 30 (2010) 318–333.

[78] I.L. King, T.L. Dickendesher, B.M. Segal, Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease, Blood 113 (2009) 3190–3197.

[79] A. Mildner, M. Mack, H. Schmidt, W. Bruck, M. Djukic, M.D. Zabel, A. Hille, J. Priller, M. Prinz, CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system, Brain 132 (2009) 2487–2500.

[80] P.D. Smith, L.E. Smythies, R. Shen, T. Greenwell-Wild, M. Gliozzi, S.M. Wahl, Intestinal macrophages and response to microbial encroachment, Mucosal Immunol. 4 (2011) 31–42.

[81] T. Lucas, A. Waisman, R. Ranjan, J. Roes, T. Krieg, W. Muller, A. Roers, S.A. Eming, Differential roles of macrophages in diverse phases of skin repair, J. Immunol. 184 (2010) 3964–3977.

[82] A.J. Cowin, M.P. Brosnan, T.M. Holmes, M.W. Ferguson, Endogenous inflammatory response to dermal wound healing in the fetal and adult mouse, Dev. Dyn. 212 (1998) 385–393.

[83] P. Martin, S.J. Leibovich, Inflammatory cells during wound repair: the good, the bad and the ugly, Trends Cell Biol. 15 (2005) 599–607.

[84] M.J. Kaplan, M. Radic, Neutrophil extracellular traps: double-edged swords of innate immunity, J. Immunol. 189 (2012) 2689–2695.

[85] J. Savill, C. Gregory, C. Haslett, Cell biology. Eat me or die, Science 302 (2003) 1516–1517.

[86] J. Savill, Apoptosis in resolution of inflammation, J. Leukoc. Biol. 61 (1997) 375–380.

[87] M.L. Huynh, V.A. Fadok, P.M. Henson, Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation, J. Clin. Invest. 109 (2002) 41–50.

[88] A.P. Castano, S.L. Lin, T. Surowy, B.T. Nowlin, S.A. Turlapati, T. Patel, A. Singh, S. Li, M.L. Lupher Jr., J.S. Duffield, Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte–macrophage regulation in vivo, Sci. Transl. Med. 1 (2009), (5ra13).

[89] J.S. Park, F. Gamboni-Robertson, Q. He, D. Svetkauskaite, J.Y. Kim, D. Strassheim, J.W. Sohn, S. Yamada, I. Maruyama, A. Banerjee, A. Ishizaka, E. Abraham, High mobility group box 1 protein interacts with multiple toll-like receptors, Am. J. Physiol. Cell Physiol. 290 (2006) C917–C924.

[90] S. Romagnani, Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? Immunol. Today 13 (1992) 379–381.

[91] Q. Cao, Y. Wang, D. Zheng, Y. Sun, V.W. Lee, G. Zheng, T.K. Tan, J. Ince, S.I. Alexander, D.C. Harris, IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis, J. Am. Soc. Nephrol. 21 (2010) 933–942.

[92] D.C. Kluth, C.V. Ainslie, W.P. Pearce, S. Finlay, D. Clarke, I. Anegon, A.J. Rees, Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis, J. Immunol. 166 (2001) 4728–4736.

[93] Y. Wang, Y.P. Wang, G. Zheng, V.W. Lee, L. Ouyang, D.H. Chang, D. Mahajan, J. Coombs, Y.M. Wang, S.I. Alexander, D.C. Harris, Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease, Kidney Int. 72 (2007) 290–299.

[94] X.R. Huang, A.R. Kitching, P.G. Tipping, S.R. Holdsworth, Interleukin-10 inhibits macrophage-induced glomerular injury, J. Am. Soc. Nephrol. 11 (2000) 262–269.

[95] F.O. Martinez, L. Helming, S. Gordon, Alternative activation of macrophages: an immunologic functional perspective, Annu. Rev. Immunol. 27 (2009) 451–483.

[96] J. Kelly, A. Ali Khan, J. Yin, T.A. Ferguson, R.S. Apte, Senescence regulates macro-phage activation and angiogenic fate at sites of tissue injury in mice, J. Clin. Invest. 117 (2007) 3421–3426.

[97] Y. Ikezumi, T. Suzuki, T. Karasawa, H. Hasegawa, H. Kawachi, D.J. Nikolic-Paterson, M. Uchiyama, Contrasting effects of steroids and mizoribine on macrophage activa-tion and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephri-tis, Am. J. Nephrol. 31 (2010) 273–282.

[98] R. Shechter, A. London, C. Varol, C. Raposo, M. Cusimano, G. Yovel, A. Rolls, M. Mack, S. Pluchino, G. Martino, S. Jung, M. Schwartz, Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice, PLoS Med. 6 (2009) e1000113.

[99] J. Shi, K. Aisaki, Y. Ikawa, K. Wake, Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride, Am. J. Pathol. 153 (1998) 515–525.

[100] F. Ren, Z. Duan, Q. Cheng, X. Shen, F. Gao, L. Bai, J. Liu, R.W. Busuttil, J.W. Kupiec-Weglinski, Y. Zhai, Inhibition of glycogen synthase kinase 3 beta amelio-rates liver ischemia reperfusion injury by way of an interleukin-10-mediated immune regulatory mechanism, Hepatology 54 (2011) 687–696.

[101] A. Leung, T.M. Crombleholme, S.G. Keswani, Fetal wound healing: implications for minimal scar formation, Curr. Opin. Pediatr. 24 (2012) 371–378.
[102] L. Yang, T.Y. Besschetnova, C.R. Brooks, J.V. Shah, J.V. Bonventre, Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury, Nat. Med. 16 (2010) 535–543, (531p following 143).
[103] R. Mirza, L.A. DiPietro, T.J. Koh, Selective and specific macrophage ablation is detrimental to wound healing in mice, Am. J. Pathol. 175 (2009) 2454–2462.
[104] R.W. Thompson, J.T. Pesce, T. Ramalingam, M.S. Wilson, S. White, A.W. Cheever, S.M. Ricklefs, S.F. Porcella, L. Li, L.G. Ellies, T.A. Wynn, Cationic amino acid transporter-2 regulates immunity by modulating arginase activity, PLoS Pathog. 4 (2008) e1000023.
[105] H. Morimoto, M. Takahashi, Y. Shiba, A. Izawa, H. Ise, M. Hongo, K. Hatake, K. Motoyoshi, U. Ikeda, Bone marrow-derived CXCR4+ cells mobilized by macrophage colony-stimulating factor participate in the reduction of infarct area and improvement of cardiac remodeling after myocardial infarction in mice, Am. J. Pathol. 171 (2007) 755–766.
[106] A.A. Filardy, D.R. Pires, M.P. Nunes, C.M. Takiya, C.G. Freire-de-Lima, F.L. Ribeiro-Gomes, G.A. DosReis, Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in macrophages, J. Immunol. 185 (2010) 2044–2050.
[107] M. Ryu, O.P. Kulkarni, E. Radomska, N. Miosge, O. Gross, H.J. Anders, Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-alpha-mediated podocyte loss, Kidney Int. 79 (2011) 189–198.
[108] S. Clauss, O. Gross, O. Kulkarni, A. Avila-Ferrufino, E. Radomska, S. Segerer, D. Eulberg, S. Klussmann, H.J. Anders, Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy, J. Pathol. 218 (2009) 40–47.
[109] M. Imamura, T. Ogawa, Y. Sasaguri, K. Chayama, H. Ueno, Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats, Gastroenterology 128 (2005) 138–146.
[110] K.R. Karlmark, R. Weiskirchen, H.W. Zimmermann, N. Gassler, F. Ginhoux, C. Weber, M. Merad, T. Luedde, C. Trautwein, F. Tacke, Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis, Hepatology 50 (2009) 261–274.
[111] V. Ninichuk, O. Gross, C. Reichel, A. Khandoga, R.D. Pawar, R. Ciubar, S. Segerer, E. Belemezova, E. Radomska, B. Luckow, G. Perez de Lema, P.M. Murphy, J.L. Gao, A. Henger, M. Kretzler, R. Horuk, M. Weber, F. Krombach, D. Schlondorff, H.J. Anders, Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease, J. Am. Soc. Nephrol. 16 (2005) 977–985.
[112] V. Ninichuk, O. Kulkarni, S. Clauss, H.J. Anders, Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy, Eur. J. Med. Res. 12 (2007) 351–355.
[113] V. Ninichuk, A.G. Khandoga, S. Segerer, P. Loetscher, A. Schlapbach, L. Revesz, R. Feifel, A. Khandoga, F. Krombach, P.J. Nelson, D. Schlondorff, H.J. Anders, The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice, Am. J. Pathol. 170 (2007) 1267–1276.
[114] V. Eis, B. Luckow, V. Vielhauer, J.T. Siveke, Y. Linde, S. Segerer, G. Perez De Lema, C.D. Cohen, M. Kretzler, M. Mack, R. Horuk, P.M. Murphy, J.L. Gao, K.L. Hudkins, C.E. Alpers, H.J. Grone, D. Schlondorff, H.J. Anders, Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction, J. Am. Soc. Nephrol. 15 (2004) 337–347.
[115] V. Vielhauer, E. Berning, V. Eis, M. Kretzler, S. Segerer, F. Strutz, R. Horuk, H.J. Grone, D. Schlondorff, H.J. Anders, CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome, Kidney Int. 66 (2004) 2264–2278.
[116] H.J. Anders, V. Vielhauer, M. Frink, Y. Linde, C.D. Cohen, S.M. Blattner, M. Kretzler, F. Strutz, M. Mack, H.J. Grone, J. Onuffer, R. Horuk, P.J. Nelson, D. Schlondorff, A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation, J. Clin. Invest. 109 (2002) 251–259.
[117] R.M. Strieter, E.C. Keeley, M.D. Burdick, B. Mehrad, The role of circulating mesenchymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis, Trans. Am. Clin. Climatol. Assoc. 120 (2009) 49–59.
[118] R. Bucala, Review series—inflammation & fibrosis. Fibrocytes and fibrosis, QJM 105 (2012) 505–508.
[119] D. Pilling, T. Fan, D. Huang, B. Kaul, R.H. Gomer, Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts, PLoS One 4 (2009) e7475.
[120] A. Andersson-Sjoland, J.S. Erjefalt, L. Bjermer, L. Eriksson, G. Westergren-Thorsson, Fibrocytes are associated with vascular and parenchymal remodelling in patients with obliterative bronchiolitis, Respir. Res. 10 (2009) 103.
[121] B. Mehrad, M.P. Keane, B.N. Gomperts, R.M. Strieter, Circulating progenitor cells in chronic lung disease, Expert Rev. Respir. Med. 1 (2007) 157–165.
[122] A. Moeller, S.E. Gilpin, K. Ask, G. Cox, D. Cook, J. Gauldie, P.J. Margetts, L. Farkas, J. Dobranowski, C. Boylan, P.M. O'Byrne, R.M. Strieter, M. Kolb, Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis, Am. J. Respir. Crit. Care Med. 179 (2009) 588–594.
[123] S.K. Mathai, M. Gulati, X. Peng, T.R. Russell, A.C. Shaw, A.N. Rubinowitz, L.A. Murray, J.M. Siner, D.E. Antin-Ozerkis, R.R. Montgomery, R.A. Reilkoff, R.J. Bucala, E.L. Herzog, Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype, Lab. Invest. 90 (2010) 812–823.
[124] R. Abe, S.C. Donnelly, T. Peng, R. Bucala, C.N. Metz, Peripheral blood fibrocytes: differentiation pathway and migration to wound sites, J. Immunol. 166 (2001) 7556–7562.
[125] L. Mori, A. Bellini, M.A. Stacey, M. Schmidt, S. Mattoli, Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow, Exp. Cell Res. 304 (2005) 81–90.
[126] M.T. Grande, J.M. Lopez-Novoa, Fibroblast activation and myofibroblast generation in obstructive nephropathy, Nat. Rev. Nephrol. 5 (2009) 319–328.
[127] Y. Ishida, J.L. Gao, P.M. Murphy, Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function, J. Immunol. 180 (2008) 569–579.
[128] M.D. Sternlicht, Z. Werb, How matrix metalloproteinases regulate cell behavior, Annu. Rev. Cell Dev. Biol. 17 (2001) 463–516.
[129] C. Verollet, G.M. Charriere, A. Labrousse, C. Cougoule, V. Le Cabec, I. Maridonneau-Parini, Extracellular proteolysis in macrophage migration: losing grip for a breakthrough, Eur. J. Immunol. 41 (2011) 2805–2813.
[130] L.R. Lund, J. Romer, T.H. Bugge, B.S. Nielsen, T.L. Frandsen, J.L. Degen, R.W. Stephens, K. Dano, Functional overlap between two classes of matrix-degrading proteases in wound healing, EMBO J. 18 (1999) 4645–4656.
[131] C. Soo, W.W. Shaw, X. Zhang, M.T. Longaker, E.W. Howard, K. Ting, Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair, Plast. Reconstr. Surg. 105 (2000) 638–647.
[132] V. Ruiz, R.M. Ordonez, J. Berumen, R. Ramirez, B. Uhal, C. Becerril, A. Pardo, M. Selman, Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis, Am. J. Physiol. Lung Cell. Mol. Physiol. 285 (2003) L1026–L1036.
[133] S. McKeown, A.G. Richter, C. O'Kane, D.F. McAuley, D.R. Thickett, MMP expression and abnormal lung permeability are important determinants of outcome in IPF, Eur. Respir. J. 33 (2009) 77–84.
[134] H. Lemjabbar, P. Gosset, E. Lechapt-Zalcman, M.L. Franco-Montoya, B. Wallaert, A. Harf, C. Lafuma, Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment, Am. J. Respir. Cell Mol. Biol. 20 (1999) 903–913.
[135] J.S. Duffield, S.J. Forbes, C.M. Constandinou, S. Clay, M. Partolina, S. Vuthoori, S. Wu, R. Lang, J.P. Iredale, Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair, J. Clin. Invest. 115 (2005) 56–65.
[136] R.J. Tan, C.L. Fattman, L.M. Niehouse, J.M. Tobolewski, L.E. Hanford, Q. Li, F.A. Monzon, W.C. Parks, T.D. Oury, Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice, Am. J. Respir. Cell Mol. Biol. 35 (2006) 289–297.
[137] P.W. Noble, C. Albera, W.Z. Bradford, U. Costabel, M.K. Glassberg, D. Kardatzke, T.E. King Jr., L. Lancaster, S.A. Sahn, J. Szwarcberg, D. Valeyre, R.M. du Bois, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet 377 (2011) 1760–1769.
[138] A. Di Sario, E. Bendia, G. Macarri, C. Candelaresi, S. Taffetani, M. Marzioni, A. Omenetti, S. De Minicis, L. Trozzi, A. Benedetti, The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2, Dig. Liver Dis. 36 (2004) 744–751.
[139] M. Corbel, J. Lanchou, N. Germain, Y. Malledant, E. Boichot, V. Lagente, Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice, Eur. J. Pharmacol. 426 (2001) 113–121.
[140] S. Cheng, D.H. Lovett, Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial–mesenchymal transformation, Am. J. Pathol. 162 (2003) 1937–1949.
[141] F. Sabeh, X.Y. Li, T.L. Saunders, R.G. Rowe, S.J. Weiss, Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion, J. Biol. Chem. 284 (2009) 23001–23011.
[142] M. Zeisberg, M. Khurana, V.H. Rao, D. Cosgrove, J.P. Rougier, M.C. Werner, C.F. Shield 3rd, Z. Werb, R. Kalluri, Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease, PLoS Med. 3 (2006) e100.
[143] P. Ronco, C. Chatziantoniou, Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives, Kidney Int. 74 (2008) 873–878.
[144] L. Sorokin, The impact of the extracellular matrix on inflammation, Nat. Rev. Immunol. 10 (2010) 712–723.
[145] D.A. Hume, K.P. MacDonald, Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling, Blood 119 (2012) 1810–1820.
[146] M. Saraiva, A. O'Garra, The regulation of IL-10 production by immune cells, Nat. Rev. Immunol. 10 (2010) 170–181.
[147] R. Lang, D. Patel, J.J. Morris, R.L. Rutschman, P.J. Murray, Shaping gene expression in activated and resting primary macrophages by IL-10, J. Immunol. 169 (2002) 2253–2263.
[148] R.D. Stout, C. Jiang, B. Matta, I. Tietzel, S.K. Watkins, J. Suttles, Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences, J. Immunol. 175 (2005) 342–349.
[149] A. O'Garra, K.M. Murphy, From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development, Nat. Immunol. 10 (2009) 929–932.
[150] S. Dillon, S. Agrawal, K. Banerjee, J. Letterio, T.L. Denning, K. Oswald-Richter, D.J. Kasprowicz, K. Kellar, J. Pare, T. van Dyke, S. Ziegler, D. Unutmaz, B. Pulendran, Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance, J. Clin. Invest. 116 (2006) 916–928.

[151] A.L. Mellor, B. Baban, P.R. Chandler, A. Manlapat, D.J. Kahler, D.H. Munn, Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling, J. Immunol. 175 (2005) 5601–5605.

[152] N. Van Rompaey, A. Le Moine, Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation, Methods Mol. Biol. 677 (2011) 169–180.

[153] Z. Zi, D.A. Chapnick, X. Liu, Dynamics of TGF-beta/Smad signaling, FEBS Lett. 586 (2012) 1921–1928.

[154] B. Bragdon, O. Moseychuk, S. Saldanha, D. King, J. Julian, A. Nohe, Bone morphogenetic proteins: a critical review, Cell. Signal. 23 (2011) 609–620.

[155] N.K. Biyikli, H. Tugtepe, F. Cakalagaoglu, A. Ilki, H. Alpay, Downregulation of the expression of bone morphogenetic protein 7 in experimental pyelonephritis, Pediatr. Nephrol. 20 (2005) 1230–1236.

[156] A.T. Dudley, K.M. Lyons, E.J. Robertson, A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye, Genes Dev. 9 (1995) 2795–2807.

[157] S. Wang, M. de Caestecker, J. Kopp, G. Mitu, J. Lapage, R. Hirschberg, Renal bone morphogenetic protein-7 protects against diabetic nephropathy, J. Am. Soc. Nephrol. 17 (2006) 2504–2512.

[158] S.E. Gould, M. Day, S.S. Jones, H. Dorai, BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells, Kidney Int. 61 (2002) 51–60.